{"name":"Atsena Therapeutics Inc.","slug":"atsena-therapeutics-inc","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":3,"colorKey":"oncology","drugs":[{"name":"ATSN-101","genericName":"ATSN-101","slug":"atsn-101","indication":"Other","status":"phase_1"},{"name":"ATSN-101 Diluent Solution","genericName":"ATSN-101 Diluent Solution","slug":"atsn-101-diluent-solution","indication":"Other","status":"phase_1"},{"name":"ATSN-201","genericName":"ATSN-201","slug":"atsn-201","indication":"Other","status":"phase_1"}]}],"pipeline":[{"name":"ATSN-101","genericName":"ATSN-101","slug":"atsn-101","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"ATSN-101 Diluent Solution","genericName":"ATSN-101 Diluent Solution","slug":"atsn-101-diluent-solution","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"ATSN-201","genericName":"ATSN-201","slug":"atsn-201","phase":"phase_1","mechanism":"Biologic","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiiAFBVV95cUxNeU1SNFphVm50Z1N0dWxLVjcwcExmakxidHh3SnRJQVhiV3ctS2JsMldmUUhtdzRVX1RtREV2VVNTSHBTdHNERFp5QVBGaWozcXp0UkY1d2ZrUmFBTlNnckRTZWpQY2pXd0dVWGxGWmIyOFo3ZlYwZllpLTJZRkVFeUQ0c2pIRW9u?oc=5","date":"2026-01-25","type":"pipeline","source":"The Business Journals","summary":"J&J VC arm, General Inception launch Cambridge biotech - The Business Journals","headline":"J&J VC arm, General Inception launch Cambridge biotech","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2025-08-05","type":"trial","source":"GlobeNewswire","summary":"AAV for the Hereditary Retinal Diseases Clinical Trial - GlobeNewswire","headline":"AAV for the Hereditary Retinal Diseases Clinical Trial","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirwFBVV95cUxNUDRSQTE5WC10a3dtU2dTak1LcnZReGVVNnF2M0stc0IwTUVlZ0tQcVlTcmY3VHJHODNqT056VmJQTUJtMVM3bTJrZXVtOE50dkk1MG0zellKYktRZUg3WTNmVUpyazNtam1SNWwwWHctbW1oVFdWaTRJVFJ4QUpOazQwOGNUQ0h2aUxTQlFadGJVSmhQZnd0M1VEdVpESFZ1QTZuNmFDN0RyUmhaZzdn?oc=5","date":"2025-04-25","type":"pipeline","source":"The Pharma Letter","summary":"LTZ bags $40 million as it sends first myeloid engager into clinic - The Pharma Letter","headline":"LTZ bags $40 million as it sends first myeloid engager into clinic","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMinAFBVV95cUxPMnRqV04zT3ZWNm5jYWsyQ2pkNFBJUWJDdzZ5SzJBeUdoTUJuaGdZNU1DX0IxdjNmdnh5dlBZZG1sWDZnSUV3c3BRbUtXWjNGajJsbVBaSDB5VktmSk1wbE9aWF8zaDFpLU4tSVRGZ08xajdEb0ZySy0taFl0WGg3YUxpQm4tMTlsbTFJWlVNb1R5WXhzMGNLQUNSNGs?oc=5","date":"2025-04-15","type":"pipeline","source":"The Pharma Letter","summary":"Attovia Therapeutics closes $90 million Series C financing - The Pharma Letter","headline":"Attovia Therapeutics closes $90 million Series C financing","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiYEFVX3lxTE52VXl1RVdITVpSLVpCZ1NBaGpjT2lCLVd4MklleUNMQmtSTHNiVW1WbGFaUDhZVVN1UjZwTTkxMDBfcmJKX3AzNXRPSi1zYnR2WXZGMXF1SFNMVGR6WFpuTw?oc=5","date":"2025-04-07","type":"pipeline","source":"The Pharma Letter","summary":"Atsena Therapeutics - The Pharma Letter","headline":"Atsena Therapeutics","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwgFBVV95cUxOS0xnY3RhaHhyLUtYYlpIRHktTEFqT0ZEeDg5WEFpWXNoakZfaEtERzdNeXo3VVNzTjg1YnE5YmkxRGtSVE9KUzVsWWt3ajBWRUI0TFBfVjZ0WlhaYkZWWFBzVFI3N2p5aGZXdUY5UFplTWZFbzJmVmdMakMwbmdVSkFqWk44d2lnRGxBZ3YydFgxWnNhcC1NYnVidEpWcDduM2ZfY2RqdHdpOE43UURiUjdWaExyRk9wMC0zb3N3NXRnQQ?oc=5","date":"2025-04-02","type":"pipeline","source":"Inside Precision Medicine","summary":"Atsena Therapeutics Secures $150M to Progress Eye Gene Therapies - Inside Precision Medicine","headline":"Atsena Therapeutics Secures $150M to Progress Eye Gene Therapies","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMingFBVV95cUxNaFBUTXBoSW9SdjV6N1ViZFc2Q09FRmo4TEptUE5mRFRIMUhqb0JDUDluN3g4aW1HYUd0VmVhVWJYM1U1Y19nUTVfTXlVSHlqMksxWTZLTXFUc1hBTVNfUTc1ZVhSa0lYaDBoRUFkS2NTSXdQUVZYRVdTYkpMc0pYbmlIYXJCYnhZRmhNbFdMQ0pxWDhKdVFqQXFZcDYzdw?oc=5","date":"2025-04-02","type":"pipeline","source":"Fierce Biotech","summary":"Atsena raises $150M for ocular gene therapies with Bain, Sofinnova in tow - Fierce Biotech","headline":"Atsena raises $150M for ocular gene therapies with Bain, Sofinnova in tow","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMioAJBVV95cUxOM1lndW1xeUNFUVVCNzNjRjk2dU5sakJSeHN4WmU1ZksyTjZWV01ndG1vZ1NnYlpydVhacTh1MFA1c3praVIzV1ZwZGlBTFVVZ0RhSTVzRzZzUDBZSVBNYlJ3am5tcFBFQy1wamJkVlpUWFdVQzdFR1R1YTAyRnNKQ2s5TFhFVWhBZUo3cXBvMU5QZXM5dzNwLVoySWZpYW9IWTFkcVJFYjlwc0c0TFZYZXBtUWQyU3JhWGtHdnFTdUlwODdyU05Dem5JSG0xQ2l0Q3FLcVdSX09RZWRIYVNTZUMxUldmaDZlaGZhWkJoUHlnNWhOR1lGX2d4UVNSTTkxRlV0Sk9iZXdxQ0kwUlAtMDdIcGZrWXpoaFRZQklVcnc?oc=5","date":"2025-04-02","type":"pipeline","source":"GlobeNewswire","summary":"Atsena Therapeutics Announces Oversubscribed $150 Million - GlobeNewswire","headline":"Atsena Therapeutics Announces Oversubscribed $150 Million","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMizgJBVV95cUxNY0F6dWlrZk5DekFxRG15YnljVkV0QkV2N21pTlFkUUJtcWdwSjFpYTNFVHFlVzVBcTVjMTdZUzhfNTNLY3JNOW5LN0dnRWh4ZmZOeUROb2FuNUd2NVFqMXlmQnVlUWk4MzduQ3REbzFlQ0dzdXV0N3JZUHMyQnBJOFU4V2RlRzE3a25ldkc5TnljU0RsYVAwc2wzRVg4S2gwSEoyeUlHWUNoSDhMcVFWYTRPNHBnRDFpdEJOZHFRa3RXVWZoTGYxLWRyYWlCSDFKRTRBTGg1cHdMZ3llVzRvcXF1RmpUbVRpa1NXWmpMWnk5ajNvN0VHdXZCTXFzOTVQZlE3dVlKTVVVSk1RVG9oZ3hfd1JoMUttTG11YncxSXVvVzc0aF8xMTRobHdRVHZKM0NuRFZjbmpHLXEwdVhHMnk3dTdrLWEyMV92Tnp3?oc=5","date":"2024-02-19","type":"trial","source":"GlobeNewswire","summary":"Gene Therapies In Ophthalmology Clinical Trial Pipeline - GlobeNewswire","headline":"Gene Therapies In Ophthalmology Clinical Trial Pipeline","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwAFBVV95cUxPWl83SjV0aUEyeVRZcnljX1ZCeHctbXZtMXRGS1FIdnU1Q05nZFNfcnplQkJkRm03cVZLYkdSSkJEZ3VYSXJUaHdHZ1lIbGhPRXVMZV9UY3EtOExhV2xZY0lLcXVwcjN6NHM0NF81WGVmYVhCUmc2SXRKejJqekY1dWJ4bGViTzFSdm5yaXhSbjNzSXB3dTBGOVBwNEYxMzBqMWtDMm9FdWZMUTEwM2RoeHg2NFhlMlN5SXB3WF94MTM?oc=5","date":"2023-10-05","type":"pipeline","source":"Fierce Biotech","summary":"Eye disease biotech Atsena downsizes to save money for retinal program testing new capsid - Fierce Biotech","headline":"Eye disease biotech Atsena downsizes to save money for retinal program testing new capsid","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirAFBVV95cUxNTWJ5UUNqWlJfTWtrU1RuNHdpTVlJUGNLWWgxYXM3OXo3dVJVWEhWRnZhVk1hYnVnNk9qLUJsTXJCd2k0aGxZS2FickxmUEFnMV9vdjJXRl9yNDF3bVJuUmlZQ3hoNDRHRE9HUHdSMGVTNDZid0JNcjZZa3hUYTEtOU1Lb0NxRHNqUVJueWJGWnBVXzVUSTZIRUg5R2Izb3VwUnN6dllWNERKakls?oc=5","date":"2022-10-04","type":"trial","source":"The Business Journals","summary":"Durham gene therapy company planning pivotal study following positive trial data - The Business Journals","headline":"Durham gene therapy company planning pivotal study following positive trial data","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMilAFBVV95cUxPQkYzZzF5Vm1MWWdzT0wzanJJU3VxNnVvclRXaEZyNzdxczJJSERuX3hHQ29teUJSSlQtb19IckRDbDY0YldFYWR2N0lmb09RQmw4ejE3MjBFUEVCQlh0RWJLN3QwUnBFUVN5SWtMTlpzSnZ6ZVNUZVJ0WFVtTUFvRU92clVucHFmVXZIUlk0Z3VsTktv?oc=5","date":"2022-08-01","type":"pipeline","source":"The Business Journals","summary":"Gene therapy firm fighting blindness expands into new space in RTP - The Business Journals","headline":"Gene therapy firm fighting blindness expands into new space in RTP","sentiment":"neutral"}],"patents":[],"drugCount":3,"phaseCounts":{"phase_1":3},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}